Ilumya vs Skyrizi
Tildrakizumab vs Risankizumab · Comparison Guide
Quick Comparison
| Feature | Ilumya | Skyrizi |
|---|---|---|
| Generic Name | Tildrakizumab | Risankizumab |
| Manufacturer | Sun Pharma | AbbVie |
| Drug Class | IL-23 Inhibitor | IL-23 Inhibitor |
| Shared Conditions | Plaque Psoriasis | |
Key Differences: Ilumya vs Skyrizi
Both target the IL-23 p19 subunit for moderate-to-severe plaque psoriasis. Skyrizi is dosed every 12 weeks and has shown high PASI 90/100 rates in trials. Ilumya is dosed every 12 weeks as well but at a lower dose (100 mg). Skyrizi also has approvals for PsA and Crohn's disease; Ilumya is only approved for psoriasis. Skyrizi has demonstrated higher skin clearance rates in indirect comparisons.
💊 Ilumya (Tildrakizumab)
- Class: IL-23 Inhibitor
- Manufacturer: Sun Pharma
- Full Ilumya information →
💊 Skyrizi (Risankizumab)
- Class: IL-23 Inhibitor
- Manufacturer: AbbVie
- Full Skyrizi information →
Both target the IL-23 p19 subunit for moderate-to-severe plaque psoriasis. Skyrizi is dosed every 12 weeks and has shown high PASI 90/100 rates in trials. Ilumya is dosed every 12 weeks as well but at a lower dose (100 mg). Skyrizi also has approvals for PsA and Crohn's disease; Ilumya is only approved for psoriasis. Skyrizi has demonstrated higher skin clearance rates in indirect comparisons.
Neither Ilumya nor Skyrizi is universally better — the right choice depends on your specific condition, disease severity, insurance formulary, and health history. Your prescriber will determine which is most appropriate based on your clinical situation. BiologicHealthPlus carries both and can help you compare your coverage and costs for either medication.
Switching between biologics is common. Your prescriber will evaluate your current treatment response and determine if a switch is appropriate. BiologicHealthPlus can coordinate the transition including prior authorization for your new medication.
Both Ilumya and Skyrizi are covered by most commercial insurance plans, Medicare Part D, and Medicaid with prior authorization. BiologicHealthPlus handles insurance verification and prior authorization for both medications at no charge. Most insured patients pay $0–$35/month through manufacturer copay programs.
Ilumya and Skyrizi both have high cash list prices ($4,000–$9,000/month range) but most commercially insured patients pay $0–$35/month through manufacturer savings programs. BiologicHealthPlus automatically enrolls every patient in all available savings programs at no charge.
✅ BiologicHealthPlus Carries Both Ilumya and Skyrizi
We handle insurance verification, prior authorization, copay enrollment, and free cold-chain delivery for both medications. Contact us and we'll help you understand your options and costs.
Medical Disclaimer: This comparison is for educational purposes only. The choice between Ilumya and Skyrizi should be made by your healthcare provider based on your specific medical history, disease severity, and individual circumstances. Last updated: July 2026.